(VIANEWS) – NVIDIA (NVDA), Terreno Realty Corporation (TRNO), Rollins (ROL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NVIDIA (NVDA)
223.7% sales growth and 69.17% return on equity
NVIDIA Corporation provides graphics, and compute and networking solutions in the United States, Taiwan, China, and internationally. The company's Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building 3D designs and virtual worlds. Its Compute & Networking segment provides Data Center platforms and systems for AI, HPC, and accelerated computing; Mellanox networking and interconnect solutions; automotive AI Cockpit, autonomous driving development agreements, and autonomous vehicle solutions; cryptocurrency mining processors; Jetson for robotics and other embedded platforms; and NVIDIA AI Enterprise and other software. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. NVIDIA Corporation sells its products to original equipment manufacturers, original device manufacturers, system builders, add-in board manufacturers, retailers/distributors, independent software vendors, Internet and cloud service providers, automotive manufacturers and tier-1 automotive suppliers, mapping companies, start-ups, and other ecosystem participants. It has a strategic collaboration with Kroger Co. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, NVIDIA has a trailing twelve months EPS of $7.6.
PE Ratio
NVIDIA has a trailing twelve months price to earnings ratio of 63.97. Meaning, the purchaser of the share is investing $63.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 69.17%.
Sales Growth
NVIDIA’s sales growth is 231.3% for the ongoing quarter and 223.7% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 205.5%, now sitting on 44.87B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 4, 2023, the estimated forward annual dividend rate is 0.16 and the estimated forward annual dividend yield is 0.03%.
Previous days news about NVIDIA(NVDA)
- NVIDIA (nvda) up 243% ytd: will it carry momentum in 2024?. According to Zacks on Tuesday, 19 December, "However, the looming question remains - Can NVIDIA sustain this momentum through 2024?", "Additionally, NVIDIA currently carries a Zacks Rank #2 (Buy) and has a Growth Score of A. Our research shows that stocks with a Growth Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or #2 offer the best investment opportunities for investors. "
- According to Zacks on Tuesday, 19 December, "Further, it recently extended its partnership with NVIDIA to offer NVIDIA GH200 Grace Hopper Superchips, and host NVIDIA DGX Cloud on Amazon Web Services (AWS) for accelerating the training of generative AI and large language models."
2. Terreno Realty Corporation (TRNO)
14.4% sales growth and 6.25% return on equity
Terreno Realty Corporation (“Terreno”, and together with its subsidiaries, “the Company”) acquires, owns and operates industrial real estate in six major coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. We invest in several types of industrial real estate, including warehouse/distribution (approximately 79.5% of our total annualized base rent as of December 31, 2021), flex (including light industrial and research and development, or R&D) (approximately 4.8%), transshipment (approximately 6.4%) and improved land (approximately 9.3%). We target functional properties in infill locations that may be shared by multiple tenants and that cater to customer demand within the various submarkets in which we operate. Infill locations are geographic locations surrounded by high concentrations of already developed land and existing buildings. As of December 31, 2021, we owned a total of 253 buildings aggregating approximately 15.1 million square feet, 36 improved land parcels consisting of approximately 127.1 acres and four properties under redevelopment that, upon completion, will consist of two properties aggregating approximately 0.2 million square feet and two improved land parcels aggregating approximately 12.1 acres. As of December 31, 2021, the buildings and improved land parcels were approximately 95.5% and 94.8% leased (including 0.4 million square feet of vacancy acquired during the fourth quarter of 2021), respectively, to 554 customers, the largest of which accounted for approximately 4.9% of our total annualized base rent.
Earnings Per Share
As for profitability, Terreno Realty Corporation has a trailing twelve months EPS of $1.9.
PE Ratio
Terreno Realty Corporation has a trailing twelve months price to earnings ratio of 30.31. Meaning, the purchaser of the share is investing $30.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.25%.
3. Rollins (ROL)
12.3% sales growth and 35.7% return on equity
Rollins, Inc., through its subsidiaries, provides pest and wildlife control services to residential and commercial customers in the United States and internationally. The company offers pest control services to residential properties protecting from common pests, including rodents, insects, and wildlife. It also provides workplace pest control solutions for customers across various end markets, such as healthcare, foodservice, and logistics. In addition, the company offers termite protection services and ancillary services. It serves clients directly, as well as through franchisee operations. Rollins, Inc. was incorporated in 1948 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Rollins has a trailing twelve months EPS of $0.83.
PE Ratio
Rollins has a trailing twelve months price to earnings ratio of 51.25. Meaning, the purchaser of the share is investing $51.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.2%, now sitting on 2.98B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 23.5% and 11.1%, respectively.
Moving Average
Rollins’s worth is way higher than its 50-day moving average of $38.39 and above its 200-day moving average of $39.44.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Rollins’s EBITDA is 7.1.
Previous days news about Rollins(ROL)
- According to Zacks on Wednesday, 20 December, "We expect four top-ranked stocks come from top-ranked sectors - Otter Tail (OTTR Quick QuoteOTTR – Free Report) , Rollins (ROL Quick QuoteROL – Free Report) , DaVita (DVA Quick QuoteDVA – Free Report) and NetEase (NTES Quick QuoteNTES – Free Report) - to realize the Fed-induced Santa Claus rally in 2023.", "Rollins - Rollins provides pest and termite control services to residential and commercial customers. "
- According to Zacks on Wednesday, 20 December, "The bottom line of Rollins outpaced estimates in three of the last four quarters and matched the mark once, the average surprise being 7.20%. ", "Shares of Palantir Technologies and Rollins have gained 20.8% and 3.6%, respectively, in the past year. "
- The zacks analyst blog highlights otter tail, rollins, davita and NetEase. According to Zacks on Thursday, 21 December, "Stocks recently featured in the blog include: Otter Tail (OTTR Quick QuoteOTTR – Free Report) , Rollins (ROL Quick QuoteROL – Free Report) , DaVita (DVA Quick QuoteDVA – Free Report) and NetEase (NTES Quick QuoteNTES – Free Report) .", "Rollins - Rollins provides pest and termite control services to residential and commercial customers. "
4. BioMarin Pharmaceutical (BMRN)
10.2% sales growth and 3.11% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $0.77.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 122.29. Meaning, the purchaser of the share is investing $122.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.11%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15%, now sitting on 2.31B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BioMarin Pharmaceutical’s EBITDA is 7.62.
Sales Growth
BioMarin Pharmaceutical’s sales growth is 18.4% for the ongoing quarter and 10.2% for the next.
5. Discover Financial Services (DFS)
10% sales growth and 25.21% return on equity
Discover Financial Services, through its subsidiaries, provides digital banking products and services, and payment services in the United States. It operates in two segments, Digital Banking and Payment Services. The Digital Banking segment offers Discover-branded credit cards to individuals; private student loans, personal loans, home loans, and other consumer lending; and direct-to-consumer deposit products comprising savings accounts, certificates of deposit, money market accounts, IRA certificates of deposit, IRA savings accounts and checking accounts, and sweep accounts. The Payment Services segment operates the PULSE, an automated teller machine, debit, and electronic funds transfer network; and Diners Club International, a payments network that issues Diners Club branded charge cards and/or provides card acceptance services, as well as offers payment transaction processing and settlement services. The company was incorporated in 1960 and is based in Riverwoods, Illinois.
Earnings Per Share
As for profitability, Discover Financial Services has a trailing twelve months EPS of $13.5.
PE Ratio
Discover Financial Services has a trailing twelve months price to earnings ratio of 8.22. Meaning, the purchaser of the share is investing $8.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.21%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 13.1%, now sitting on 10.44B for the twelve trailing months.
Volume
Today’s last reported volume for Discover Financial Services is 509491 which is 78.64% below its average volume of 2385650.
Yearly Top and Bottom Value
Discover Financial Services’s stock is valued at $110.97 at 04:22 EST, below its 52-week high of $122.50 and way higher than its 52-week low of $79.04.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 31.8% and a negative 4.2%, respectively.
6. Ares Capital (ARCC)
9.9% sales growth and 12.67% return on equity
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.
Earnings Per Share
As for profitability, Ares Capital has a trailing twelve months EPS of $2.31.
PE Ratio
Ares Capital has a trailing twelve months price to earnings ratio of 8.47. Meaning, the purchaser of the share is investing $8.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.67%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 13, 2023, the estimated forward annual dividend rate is 1.92 and the estimated forward annual dividend yield is 10.28%.
Sales Growth
Ares Capital’s sales growth is 6% for the ongoing quarter and 9.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22%, now sitting on 2.55B for the twelve trailing months.
Previous days news about Ares Capital(ARCC)
- Ares capital (arcc) stock sinks as market gains: here's why. According to Zacks on Tuesday, 19 December, "The investment community will be paying close attention to the earnings performance of Ares Capital in its upcoming release. ", "On that day, Ares Capital is projected to report earnings of $0.59 per share, which would represent a year-over-year decline of 6.35%. "
7. Copa Holdings, S.A. Copa Holdings, S.A. (CPA)
7.2% sales growth and 24.37% return on equity
Copa Holdings, S.A., through its subsidiaries, provides airline passenger and cargo services. The company offers approximately 104 daily scheduled flights to 54 destinations in 25 countries in North, Central, and South America, as well as the Caribbean from its Panama City hub. As of December 31, 2020, it operated a fleet of 77 aircraft comprising 70 Boeing 737-Next Generation aircraft and 7 Boeing 737 MAX 9 aircraft. Copa Holdings, S.A. was founded in 1947 and is based in Panama City, Panama.
Earnings Per Share
As for profitability, Copa Holdings, S.A. Copa Holdings, S.A. has a trailing twelve months EPS of $9.7.
PE Ratio
Copa Holdings, S.A. Copa Holdings, S.A. has a trailing twelve months price to earnings ratio of 10.87. Meaning, the purchaser of the share is investing $10.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.37%.
Yearly Top and Bottom Value
Copa Holdings, S.A. Copa Holdings, S.A.’s stock is valued at $105.40 at 04:22 EST, way below its 52-week high of $121.20 and way above its 52-week low of $78.12.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 29, 2023, the estimated forward annual dividend rate is 3.28 and the estimated forward annual dividend yield is 3.15%.
